Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.

Jimin RenRichard B DeweyAustin RyndersJacob EvanJeremy EvanShelia LigozioKaren S HoPeter V SguignaRobert GlanzmanMichael T HotchkinRichard B DeweyBenjamin M Greenberg

Published in: Journal of nanobiotechnology (2024)

Keyphrases

multiple sclerosis
clinical trial
white matter
phase ii
resting state
social media
sensitive detection
cancer therapy
functional connectivity
reduced graphene oxide
cerebral ischemia
randomized controlled trial
drug delivery
gold nanoparticles
phase iii
brain injury
quantum dots